UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The association between phthalates and metabolic syndrome: the National Health and Nutrition Examination Survey 2001-2010

Environmental health, 2016-04, Vol.15 (39), p.52-52, Article 52

2016

Volltextzugriff (PDF)

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design

Journal of cachexia, sarcopenia and muscle, 2024-06, Vol.15 (3), p.1054-1061

2024

Volltextzugriff (PDF)

Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology

Clinical therapeutics, 2023-01, Vol.45 (1), p.55-70

2023

Volltextzugriff (PDF)

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial

Obesity science & practice, 2021-06, Vol.7 (3), p.281-290

2021

Volltextzugriff (PDF)

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Nature medicine, 2021-06, Vol.27 (6), p.1079-1087

2021

Volltextzugriff (PDF)

Gender and racial/ethnic differences in the associations of urinary phthalate metabolites with markers of diabetes risk: National Health and Nutrition Examination Survey 2001-2008

Environmental health, 2014-02, Vol.13 (1), p.6-6, Article 6

2014

Volltextzugriff (PDF)

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2023-03, Vol.25 (3), p.805-814

2023

Volltextzugriff (PDF)

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Diabetes, obesity & metabolism, 2023-10, Vol.25 (10), p.2805-2814

2023

Volltextzugriff (PDF)

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide‑1 Receptor

Journal of medicinal chemistry, 2022-06, Vol.65 (12), p.8208-8226

2022

Volltextzugriff (PDF)

339-OR: Oral Small-Molecule GLP-1R Agonist Danuglipron Robustly Reduces Plasma Glucose and Body Weight after Eight Weeks in Japanese Adults with Type 2 Diabetes Mellitus

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.992-1001

2023

Volltextzugriff (PDF)

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies

Diabetes, obesity & metabolism, 2024-08, Vol.26 (8), p.3155-3166

2024

Volltextzugriff (PDF)

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

JAMA network open, 2023-05, Vol.6 (5), p.e2314493-e2314493

2023

Volltextzugriff (PDF)

Ponsegromab for the Treatment of Cancer Cachexia

The New England journal of medicine, 2024-09

2024

Volltextzugriff (PDF)

Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes

Journal of clinical pharmacology, 2024-04, Vol.64 (4), p.449-460

2024

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

Clinical pharmacology in drug development, 2020-05, Vol.9 (4), p.514-526

2020

Volltextzugriff (PDF)

Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy

Hypertension (Dallas, Tex. 1979), 2010-05, Vol.55 (5), p.1239-1245

2010

Volltextzugriff (PDF)

The Association of Estrogen Receptor-β Gene Variation With Salt-Sensitive Blood Pressure

The journal of clinical endocrinology and metabolism, 2017-11, Vol.102 (11), p.4124-4135

2017

Volltextzugriff (PDF)

Luteinizing hormone correlates with adrenal function in postmenopausal women

Menopause (New York, N.Y.), 2012-11, Vol.19 (11), p.1280-1283

2012

Volltextzugriff (PDF)

Labor therapeutics and BMI as risk factors for postpartum preeclampsia: A case-control study

Pregnancy hypertension, 2017-10, Vol.10, p.177-181

2017

Volltextzugriff (PDF)

First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia

BMC pregnancy and childbirth, 2013-04, Vol.13 (1), p.85-85, Article 85

2013

Volltextzugriff (PDF)

Smoking cessation and associated risk of metabolic syndrome in women

Women's health (London, England), 2012-07, Vol.8 (4), p.367-369

2012

Volltextzugriff (PDF)

Predictors of plasma and urinary catecholamine levels in normotensive and hypertensive men and women

Journal of human hypertension, 2014-05, Vol.28 (5), p.292-297

2014

Volltextzugriff (PDF)

The Association of Estrogen Receptor-[beta] Gene Variation With Salt-Sensitive Blood Pressure

The journal of clinical endocrinology and metabolism, 2017-11, Vol.102 (11), p.4124

2017

Volltextzugriff (PDF)

Correlation of Cystatin-C with Glomerular Filtration Rate by Inulin Clearance in Pregnancy

Hypertension in pregnancy, 2012-02, Vol.31 (1), p.22-30

2012

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The association between phthalates and metabolic syndrome: the National Health and Nutrition Examination Survey 2001-2010

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design

Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Gender and racial/ethnic differences in the associations of urinary phthalate metabolites with markers of diabetes risk: National Health and Nutrition Examination Survey 2001-2008

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide‑1 Receptor

339-OR: Oral Small-Molecule GLP-1R Agonist Danuglipron Robustly Reduces Plasma Glucose and Body Weight after Eight Weeks in Japanese Adults with Type 2 Diabetes Mellitus

A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

Ponsegromab for the Treatment of Cancer Cachexia

Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy

The Association of Estrogen Receptor-β Gene Variation With Salt-Sensitive Blood Pressure

Luteinizing hormone correlates with adrenal function in postmenopausal women

Labor therapeutics and BMI as risk factors for postpartum preeclampsia: A case-control study

First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia

Smoking cessation and associated risk of metabolic syndrome in women

Predictors of plasma and urinary catecholamine levels in normotensive and hypertensive men and women

The Association of Estrogen Receptor-[beta] Gene Variation With Salt-Sensitive Blood Pressure

Correlation of Cystatin-C with Glomerular Filtration Rate by Inulin Clearance in Pregnancy

Suchergebnisse filtern